{"id":24867,"date":"2014-06-06T05:45:58","date_gmt":"2014-06-06T09:45:58","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=24867"},"modified":"2014-06-06T05:45:58","modified_gmt":"2014-06-06T09:45:58","slug":"bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867","title":{"rendered":"Bristol-Myers Squibb Co (NYSE:BMY) And Cytomx Therapeutics Collaborated For Developing Probody\u2122 Therapeutics"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 06\/06\/2014 (wallstreetpr)\u00a0\u2013\u00a0<strong>Bristol-Myers Squibb Co (NYSE:BMY)<\/strong> entered into an agreement with CytomX Therapeutics, Inc on May 27, 2014. BMY announced that the two companies signed worldwide research collaboration and license agreement in order to discover, develop as well as commercialise new therapies against the multiple immuno-oncology targets. This will be done by making use of Probody\u2122 Platform, a proprietary product of CytomX Therapeutics.<\/p>\n<p style=\"text-align: justify;\"><b>Terms of Agreement<\/b><\/p>\n<ul style=\"text-align: justify;\">\n<li>As per the signed agreement, CytomX will allow Bristol-Myers Squibb Co (NYSE:BMY)\u00a0to make use of CytomX\u2019s exclusive worldwide rights for development as well as commercialisation of Probodies for until four oncology targets which also include CTLA-4. CTLA-4 is basically a clinically authorised immune inhibitory checkpoint receptor.<\/li>\n<li>Apart from this, BMY will have a few other rights for substituting a maximum of two collaboration targets.<\/li>\n<li>As per the agreement, BMY will make upfront payment to CytomX worth $50 million. BMY will also facilitate research funding to CytomX for the period of ongoing research.<\/li>\n<li>As a part of the agreement, CytomX will become eligible to receive additional preclinical payments as well as up to $298 million for future development, sales milestone payments as well as regulatory milestone payments for every collaboration target.<\/li>\n<li>The transaction will be completed subject to a few customary conditions which include clearance from the authorised body under Hart-Scott-Rodino Antitrust Improvements Act.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><b>Statement from Executive Vice President and Chief Scientific Officer, Bristol-Myers Squibb<\/b><\/p>\n<p style=\"text-align: justify;\">The Executive Vice President and Chief Scientific Officer of Bristol-Myers Squibb Co (NYSE:BMY), Francis Cuss, said that the immuno-oncology is capable of offering a huge range of opportunities for changing the way cancers are treated. He explained that his company was working in line with the target of advancing the immuno-oncology drug research as well as development for the cancer patients. He further explained that the Probody Platform was capable of broadening the discovery of innovative therapies and that BMY\u2019s collaboration with CytomX reflected his company\u2019s leadership in the immuno-oncology branch.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 06\/06\/2014 (wallstreetpr)\u00a0\u2013\u00a0Bristol-Myers Squibb Co (NYSE:BMY) entered into an agreement with CytomX Therapeutics, Inc on May 27, 2014. BMY announced that the two companies [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":24868,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[3685,997],"stock_ticker":[],"class_list":["post-24867","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-bristol-myers-squibb-co-nysebmy","tag-nysebmy","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bristol-Myers Squibb Co (NYSE:BMY) And Cytomx Therapeutics Collaborated For Developing Probody\u2122 Therapeutics  - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bristol-Myers Squibb Co (NYSE:BMY) And Cytomx Therapeutics Collaborated For Developing Probody\u2122 Therapeutics  - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 06\/06\/2014 (wallstreetpr)\u00a0\u2013\u00a0Bristol-Myers Squibb Co (NYSE:BMY) entered into an agreement with CytomX Therapeutics, Inc on May 27, 2014. BMY announced that the two companies [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-06-06T09:45:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Bristol-Myers-Squibb-Co.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"259\" \/>\n\t<meta property=\"og:image:height\" content=\"194\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Donna Fago\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Donna Fago\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867\"},\"author\":{\"name\":\"Donna Fago\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\"},\"headline\":\"Bristol-Myers Squibb Co (NYSE:BMY) And Cytomx Therapeutics Collaborated For Developing Probody\u2122 Therapeutics\",\"datePublished\":\"2014-06-06T09:45:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867\"},\"wordCount\":338,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Bristol-Myers-Squibb-Co.jpg\",\"keywords\":[\"Bristol-Myers Squibb Co (NYSE:BMY)\",\"NYSE:BMY\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867\",\"name\":\"Bristol-Myers Squibb Co (NYSE:BMY) And Cytomx Therapeutics Collaborated For Developing Probody\u2122 Therapeutics - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Bristol-Myers-Squibb-Co.jpg\",\"datePublished\":\"2014-06-06T09:45:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Bristol-Myers-Squibb-Co.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Bristol-Myers-Squibb-Co.jpg\",\"width\":259,\"height\":194},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bristol-Myers Squibb Co (NYSE:BMY) And Cytomx Therapeutics Collaborated For Developing Probody\u2122 Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\",\"name\":\"Donna Fago\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"caption\":\"Donna Fago\"},\"description\":\"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.\",\"sameAs\":[\"http:\/\/www.WallStreetPR.com\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bristol-Myers Squibb Co (NYSE:BMY) And Cytomx Therapeutics Collaborated For Developing Probody\u2122 Therapeutics  - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867","og_locale":"en_US","og_type":"article","og_title":"Bristol-Myers Squibb Co (NYSE:BMY) And Cytomx Therapeutics Collaborated For Developing Probody\u2122 Therapeutics  - Wall Street PR","og_description":"Boston, MA 06\/06\/2014 (wallstreetpr)\u00a0\u2013\u00a0Bristol-Myers Squibb Co (NYSE:BMY) entered into an agreement with CytomX Therapeutics, Inc on May 27, 2014. BMY announced that the two companies [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-06-06T09:45:58+00:00","og_image":[{"width":259,"height":194,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Bristol-Myers-Squibb-Co.jpg","type":"image\/jpeg"}],"author":"Donna Fago","twitter_misc":{"Written by":"Donna Fago","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867"},"author":{"name":"Donna Fago","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84"},"headline":"Bristol-Myers Squibb Co (NYSE:BMY) And Cytomx Therapeutics Collaborated For Developing Probody\u2122 Therapeutics","datePublished":"2014-06-06T09:45:58+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867"},"wordCount":338,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Bristol-Myers-Squibb-Co.jpg","keywords":["Bristol-Myers Squibb Co (NYSE:BMY)","NYSE:BMY"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867","url":"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867","name":"Bristol-Myers Squibb Co (NYSE:BMY) And Cytomx Therapeutics Collaborated For Developing Probody\u2122 Therapeutics - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Bristol-Myers-Squibb-Co.jpg","datePublished":"2014-06-06T09:45:58+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Bristol-Myers-Squibb-Co.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Bristol-Myers-Squibb-Co.jpg","width":259,"height":194},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/bristol-myers-squibb-co-nysebmy-and-cytomx-therapeutics-collaborated-for-developing-probody-therapeutics-24867#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Bristol-Myers Squibb Co (NYSE:BMY) And Cytomx Therapeutics Collaborated For Developing Probody\u2122 Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84","name":"Donna Fago","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","caption":"Donna Fago"},"description":"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.","sameAs":["http:\/\/www.WallStreetPR.com"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/24867","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=24867"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/24867\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/24868"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=24867"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=24867"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=24867"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=24867"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}